OrthoLogic Corporation Release: Chrysalin (Rusalatide Acetate, TP508) Pre-Clinical Results Show Significant Beneficial Effect in Chronic Heart Disease

TEMPE, Ariz., Sept. 3, 2008 (GLOBE NEWSWIRE) -- OrthoLogic Corp. (Nasdaq:OLGC) announced today the publication of positive results from a pre-clinical study of Chrysalin(r) (rusalatide acetate or TP508) in a model of chronic myocardial ischemia. The study demonstrates that Chrysalin significantly increases vascular perfusion and myocardial function in porcine hearts with induced chronic myocardial ischemia.